Compare Alphabet Inc Class A (GOOGL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Recursion Pharmaceuticals Inc — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Alphabet Inc Class A is far larger — about 1981.3× Recursion Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GOOGL | RXRX | |
|---|---|---|
Market Cap | $4.24T | $2.14B |
Volume | 23,392,850 | 30,789,535 |
Sector | Media | Health |
52-Week High | $402.62 | $6.79 |
52-Week Low | $236.59 | $2.84 |
Typical Hold Time | 85 Days | 23 Days |
Enterprise Value | $4.13T | $1.66B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, amid strong fundamental performance with Q2 2026 EPS beating expectations by 217%. The stock shows bullish technical signals with moving averages supporting upward momentum, while maintaining robust profitability metrics including 54.77% net income margin and 49.55% ROE. Recent developments include YouTube subscription price increases and AI infrastructure partnerships driving growth prospects.
With 87% analyst buy ratings and a $431.83 consensus target representing 24% upside, GOOGL presents compelling value at current levels. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and consistent earnings beats support long-term growth trajectory. The company's diversified revenue streams and AI leadership position it well for sustained outperformance.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
